Surface plasmon resonance

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

Introducing Assay Performance Monitoring for the Automated Assessment of Assay Data Quality in Real Time

Retrieved on: 
Monday, March 4, 2024
Bias, Artificial intelligence, Information management, Drug discovery, Assay, Quality control, ELN, Surface plasmon resonance, Classification, Organization, Automation, BLI, SPR, Fine chemical

BASEL, Switzerland, March 4, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced a new release of Genedata Screener®, its enterprise platform for automated assay data analytics and consolidated assay information management across an enterprise. The new version features as a new module, Assay Performance Monitoring, the first commercially available solution for monitoring assay data quality in the context of historical data. Included in the most comprehensive assay analytics platform on the market, Genedata Screener 21 sets new standards for data quality assessment and automated data processing that produce higher result quality, accelerated workflows coupled with increased consistency, improved scientific efficiency, and shortened timelines for molecule discovery and development.

Key Points: 
  • The new version features as a new module, Assay Performance Monitoring, the first commercially available solution for monitoring assay data quality in the context of historical data.
  • Developed in close collaboration with leading biopharma companies, Genedata Screener 21 offers a new integrated solution for continuous assessment of assay quality, enabling the automated identification of experimental issues without delay.
  • Without a suitable enterprise solution, assay scientists spend hours manually compiling assay performance data, often bouncing between software tools.
  • Routine assay performance assessment in Screener using the new Assay Performance Monitoring module follows industry best-practices and ensures that assay quality standards are met without the need for manual data compilation.

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Retrieved on: 
Monday, February 5, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Professional Services, Other Science, Research, Medical Devices, General Health, Data Analytics, Health Technology, Science, Data Management, Multimedia, Microfluidics, Kinetics, Fraunhofer Society, BRKR, SPR, Cell therapy, Surface plasmon resonance, Thermodynamics, Bruker, Drug, Drug discovery, Exhibition, Immunology, API, Acquisition, Automation, Software, Conference

At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.

Key Points: 
  • At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
  • The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality.
  • View the full release here: https://www.businesswire.com/news/home/20240205314598/en/
    ‘Triceratops’ SPR #64: the all new, high-throughput multiplexing Surface Plasmon Resonance (SPR) system (Photo: Business Wire)
    The ‘Triceratops’ SPR #64 system combines highest sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the 8-channel flow cell, now facilitates the simultaneous reading of 64 sensor spots.
  • With the ‘Triceratops’ SPR #64, Bruker is now offering drug discovery customers the highest throughput in the industry with uncompromising data quality.

Proteomics Reagents Dominate Market, While Drug Discovery Applications Exhibit Highest Growth Rate - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Pharmaceutical, Health, Research, Growth, Proteomics, Chromatography, Government, Drug discovery, Prevalence, End, Protein microarray, Developed country, Protein, R, Artificial intelligence, Genomics, COVID-19, DSM-IV codes, Hospital, Traction, TAT, Surface plasmon resonance, Instrument, Patient, Medical device, Pharmaceutical industry, Fine chemical, Electrophoresis, Investment, Cancer

Faster Turn-around Times (TAT): Proteomics technologies enable faster turn-around times in diagnostics and drug discovery, facilitating quicker patient management and pharmaceutical development.

Key Points: 
  • Faster Turn-around Times (TAT): Proteomics technologies enable faster turn-around times in diagnostics and drug discovery, facilitating quicker patient management and pharmaceutical development.
  • Increased Investments in R&D in the Field of Proteomics: Research and development activities in proteomics have witnessed significant investments, driving innovation and market growth.
  • Surge in Drug Discovery: Proteomics technologies are increasingly being used to accelerate drug discovery processes, leading to the development of novel therapeutic agents.
  • The drug discovery segment is also expected to exhibit the highest CAGR in the future, as proteomics technologies offer early insights into drug discovery programs, saving pharmaceutical companies significant capital and benefiting patients and healthcare systems.

Global Label Free Detection Industry Research Report 2023: An $860+ Million Market by 2028 - Biosensor Chips Pave the Way in Label-Free Detection Consumables

Retrieved on: 
Tuesday, August 29, 2023
DNA, Drug development, Biochemistry, Surface plasmon, AMETEK, Enzyme, Sartorius AG, Research, University, Biomedical engineering, Surface plasmon resonance, USD, Princeton University, Proteomics, Danaher Corporation, Science, Organization, Student, PerkinElmer, Faculty, Knowledge, Growth, Waters Corporation, Region, ChromeOS, Pharmaceutical industry, Medical imaging, Software

Prominent players operating in the label-free detection market are Danaher Corporation (US), Sartorius AG (Germany), Waters Corporation (US), PerkinElmer Inc. (US), and AMETEK, Inc. (US).

Key Points: 
  • Prominent players operating in the label-free detection market are Danaher Corporation (US), Sartorius AG (Germany), Waters Corporation (US), PerkinElmer Inc. (US), and AMETEK, Inc. (US).
  • In 2022, biosensor chips segment accounted for the largest share by consumables in the global label-free detection market.
  • The European label-free detection market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion.
  • Europe is at the forefront of developing and adopting emerging technologies in the field of label-free detection market.

Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)

Retrieved on: 
Monday, July 17, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Single, Central nervous system, Therapy, SPR, Pathology, SAD, Bristol Myers Squibb, Brain, Surface plasmon resonance, CNS, Plasma, AAIC, Clinical trial, Fluid mechanics, Patient, Donanemab, MAD, CSF, Pharmaceutical industry, Vaccine

Our posters at AAIC exemplify our multiple efforts to continue bringing innovation to the Alzheimer’s disease field,” said Wagner Zago, Ph.D., Chief Scientific Officer, Prothena.

Key Points: 
  • Our posters at AAIC exemplify our multiple efforts to continue bringing innovation to the Alzheimer’s disease field,” said Wagner Zago, Ph.D., Chief Scientific Officer, Prothena.
  • On July 10, 2023, Prothena announced that Bristol Myers Squibb exercised its $55 million option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005.
  • All program updates, including results from ongoing and any future PRX005 clinical studies, will be reported by Bristol Myers Squibb going forward.
  • In the second study, ex vivo using post-mortem Alzheimer’s disease brain tissue, PRX012s demonstrated to robustly clear pyroglutamate-modified Aβ deposited in plaques more potently than donanemab.

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

Retrieved on: 
Monday, July 17, 2023
Volunteering, PMN, Plaque, Therapy, PROMIS, AAN, Pharmacokinetics, American Academy, Multiple system atrophy, Solanezumab, QS-21, Antibody, Incidence, Meningoencephalitis, AAIC, ARIA, Patient, Immunoglobulin G, MSA, Risk, Poster, Neuroscience, Epitope, TSX, Abo, Surface plasmon resonance, FDA, American Academy of Neurology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ALS, IND, Food, Safety, Conference, Vaccine, Pharmaceutical industry, Paint, Publication

Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO.

Key Points: 
  • Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO.
  • The data were presented in posters on July 16, 2023, at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, Netherlands.
  • “The increasingly recognized benefit of targeting oligomers of Aβ underscores the potential advantage of our PMN310 antibody and AβO vaccine candidates.
  • ProMIS presented a poster on its vaccine candidate being evaluated preclinically for the prevention of AD at AAIC.

NanoTemper Technologies Unveils Biotinylated Target Labeling Kit, Empowering Scientists in Pharma Industry to Tackle Challenging Drug Targets

Retrieved on: 
Thursday, June 29, 2023
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Shift, Redshift, Drug discovery, Spectral, Surface plasmon resonance, Protein, Monolith, SPR, Pharmaceutical industry, Dianthus

NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry.

Key Points: 
  • NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry.
  • This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal method for scientists utilizing surface plasmon resonance (SPR), who predominantly use biotinylated proteins for affinity screening or binding affinity assays.
  • “Now, direct comparison of binding affinities from an immobilized method to the in-solution, immobilization-free technique of Spectral Shift is possible,” says Regina Borovac, Consumables Product Manager at NanoTemper Technologies.
  • For more information about the Biotinylated Target Labeling Kits and other groundbreaking solutions like Dianthus and Monolith X from NanoTemper Technologies, please visit nanotempertech.com .

AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

Retrieved on: 
Thursday, June 15, 2023
2022–2023 monkeypox outbreak, Graft-versus-host disease, GVHD, NOAEL, Therapy, Federation of Clinical Immunology Societies, CD3, ICE, TT, Survival, Psoriasis, Inflammation, ELISA, P-selectin, DTH, Psoriatic arthritis, Patient, Ulcerative colitis, Tetanus, SAN, Toxicology, Mouse, NHP, Surface plasmon resonance, Research, Skin, Safety, Pharmaceutical industry, Vaccine

ALTB-268 is engineered to be a tetravalent version of its predecessor ALTB-168 and has a similar mechanism of action.

Key Points: 
  • ALTB-268 is engineered to be a tetravalent version of its predecessor ALTB-168 and has a similar mechanism of action.
  • ALTB-268, a tetravalent version of ALTB-168 demonstrated greater than 10-fold higher potency in in vitro T cell activation inhibition assays compared to ALTB-168.
  • The preclinical data will highlight a new role for PSGL-1 as a novel immune checkpoint regulator that modulates T cell homeostasis.
  • ALTB-168 has been clinically validated for safety, tolerability, and efficacy in treating inflammatory diseases including Psoriasis, Psoriatic Arthritis, Ulcerative Colitis and acute GVHD.